Attis Announces Collaboration with Novozymes to Provide Bio-technology for Ethanol Production at its Biorefineries
January 16 2019 - 8:30AM
via NEWMEDIAWIRE -- Attis Industries
Inc.(NASDAQ: ATIS) (the "Company" or "Attis"), a diversified
innovation and technology holding company today announced it will
collaborate with Novozymes A/S(NASDAQ
OXM: NZYM-B,OTCPK:NVZMF), a world leader in biotechnology for
renewable fuel production. Under this newly announced
relationship, Novozymes has committed to supplying the enzymes
required by Attis to convert its pulp into sugar at all of its
planned biorefineries. Novozymes has a broad portfolio
of biotechnology to support commercial cellulosic biofuels
production, and the ability to ramp up production as needed in an
effort to support Attis' ambitious growth plans.
Attis has successfully converted the pulp
extracted from its patented biomass processing into high yields of
sugar using Novozymes’ proprietary enzyme
cocktails. These successful results have validated the
planned business model at Attis' biorefineries. The
partnership will focus on improving value, yields, and process
efficiencies. The sugars that will be produced using
Novozymes’ proprietary enzymes will, in turn, be used to
manufacture cellulosic ethanol and help contribute to a growing
market for cellulosic biofuels under the EPA's Renewable Fuel
Standard.
Attis and Novozymes’ initial collaboration will
focus on optimizing the value of the biotechnology utilized in the
Attis process, enabling Attis to meet the growing demand for
advanced biofuels. The current Renewable Fuel Standard
calls for the production of 16 billion gallons of cellulosic
biofuels by the year 2022, however, the renewable fuel industry has
not been consistently able to produce 1 billion gallons on an
annual basis. Attis believes this is a tremendous market
opportunity where with the combination of Attis' patented biomass
processing technology and Novozymes’ proprietary enzymes can forge
a new standard for renewable fuel production in the United
States.
"Attis is very excited about forming a partnership
with Novozymes for the efficient production of ethanol at future
biorefineries," stated Jeff Cosman, Chief Executive Officer of
Attis Industries. "Novozymes is the industry leader in
biotechnology for the renewable fuel industry and brings with it
unquestioned credibility to our renewable fuel goals and also
shares a similar innovation vision. We look forward to
growing our relationship as we continue the deployment of our
biorefineries across the country."
About Attis Industries Inc.
Attis Industries Inc. (NASDAQ: ATIS) is a
holding company focused on developing and building businesses that
play important roles in the new economy, which include renewable
fuels, bio-based plastics, healthcare and communications
infrastructure. We strive to encourage our employees to be
entrepreneurs focused on innovation and technology. We will remain
dynamic, persistent and motivated to our mission of winning. The
growth of our company will rely on our integrity and our vision for
the future. Attis Industries will continue to fulfill essential
needs in healthcare, energy independence and digital
communications. Today, each of these sectors provide high growth
opportunities that collectively account for more than a third of
America’s GDP. For more information,
visit: www.attisind.com.
About Novozymes
Novozymes is the world leader in biological
solutions. Together with customers, partners and the global
community, we improve industrial performance while preserving the
planet's resources and helping build better lives. As the world's
largest provider of enzyme and microbial technologies, our
bioinnovation enables higher agricultural yields, low-temperature
washing, energy-efficient production, renewable fuel, and many
other benefits that we rely on today and in the future. We call it
Rethink Tomorrow. www.novozymes.comNASDAQ OMX: NZYM-B • 6,500
employees • DKK 14,5 billion turnover • 30+ industries • 700+
products
http://www.novozymes.com/en/news/news-archive/2018/10/science-magazine-novozymes-is-top-three-best-employer-in-the-world
Forward-Looking Statements
Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. You can identify
forward-looking statements by words such as “anticipate,”
“believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“should,” “would” or similar words. You should consider these
statements carefully because they discuss our plans, targets,
strategies, prospects and expectations concerning our business,
operating results, financial condition and other similar matters.
These statements are subject to certain risks, uncertainties, and
assumptions, including, but not limited to, risks and uncertainties
relating to the Company's ability to develop, market and sell
products based on its technology; the expected benefits and
efficacy of the Company's products and technology; the availability
of substantial additional funding for the Company to continue its
operations and to conduct research and development, clinical
studies and future product commercialization; and, the Company's
business, research, product development, regulatory approval,
marketing and distribution plans and strategies; the ability of the
Company to continue to meet the listing requirements of NASDAQ; the
ability of the Company to execute on a business plan that permits
the technologies and innovations businesses to provide sufficient
growth, revenue, liquidity and cash flows for sustaining the
Company’s go-forward business, and the risks identified and
discussed under the caption “Risk Factors” in the Attis Annual
Report on Form 10-K for the fiscal year ended December 31, 2017,
filed with the Securities and Exchange Commission (the “SEC”) on
April 16, 2018 and the other documents Attis files with the SEC
from time to time. There will be events in the future, however,
that Attis is not able to predict accurately or control. Attis’s
actual results may differ materially from the expectations that
Attis describes in its forward-looking statements. Factors or
events that could cause Attis’s actual results to materially differ
may emerge from time to time, and it is not possible for Attis to
accurately predict all of them. Any forward-looking statement made
by Attis in this press release speaks only as of the date on which
Attis makes it. Attis undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
Kevin M. McGrath (Investors)
212 389 9782 x104
kevin@traditigalir.com
Sean Leous (Media)
212 389 9782 x102
sean@tradigitalir.com
Stephen Hart
Hayden IR
(917) 658-7878
hart@haydenir.com
Attis Industries (NASDAQ:ATIS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Attis Industries (NASDAQ:ATIS)
Historical Stock Chart
From Sep 2023 to Sep 2024